BLAINJECTIONINJECTABLE
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
HYRIMOZ (adalimumab-adaz) by Novartis is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2018.
Drug data last refreshed 13h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYRIMOZ is a TNF-blocker monoclonal antibody indicated for autoimmune and inflammatory conditions, approved in 2018 as an adalimumab biosimilar. It works by blocking tumor necrosis factor receptor activity to reduce inflammation and immune-mediated disease progression. The product targets patients with rheumatoid arthritis, psoriasis, Crohn's disease, and other TNF-driven conditions.
Peak
HYRIMOZ is at peak lifecycle maturity in a crowded TNF-blocker market, suggesting stable but competitive commercial operations with emphasis on managed care and patient access.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
Started Feb 2023
562 enrolled
Inflammatory Bowel Disease
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Started Jun 2019
63 enrolled
Crohn´s Disease
Career Relevance
Working on HYRIMOZ offers stable, high-pressure commercial execution in a crowded biosimilar market where success depends on managed care partnerships, physician education, and cost-competitive positioning. The role is ideal for professionals comfortable with market defense and incremental innovation rather than breakthrough development.
Worked on HYRIMOZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.